Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-22
2010-12-14
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07851486
ABSTRACT:
Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
REFERENCES:
patent: 4970215 (1990-11-01), Mohrs et al.
patent: 5059609 (1991-10-01), Eggler et al.
patent: 5298512 (1994-03-01), Eggler et al.
patent: 5306820 (1994-04-01), Decker et al.
patent: 5527827 (1996-06-01), Delorme et al.
patent: 5559134 (1996-09-01), Buchmann et al.
patent: 5576338 (1996-11-01), Friesen et al.
patent: 5641789 (1997-06-01), Marfat
patent: 5939529 (1999-08-01), Potempa
patent: 5981559 (1999-11-01), Nagaoka et al.
patent: 5990148 (1999-11-01), Isakson et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6166031 (2000-12-01), Eggler et al.
patent: 6436924 (2002-08-01), Poppe et al.
patent: 6521747 (2003-02-01), Anastasio et al.
patent: 6531279 (2003-03-01), Blumenfeld et al.
patent: 6797475 (2004-09-01), Barnes et al.
patent: 2002/0107276 (2002-08-01), Isakson et al.
patent: 2003/0194721 (2003-10-01), Mikita et al.
patent: 2003/0225155 (2003-12-01), Fernandez-Pol et al.
patent: 2004/0014759 (2004-01-01), Picard et al.
patent: 2004/0053983 (2004-03-01), Barvian et al.
patent: 2337571 (2002-08-01), None
patent: 4118014 (1992-12-01), None
patent: 4118173 (1992-12-01), None
patent: 4127842 (1993-02-01), None
patent: 100 07203 (2001-08-01), None
patent: 0 360 246 (1990-03-01), None
patent: 0 518 819 (1992-12-01), None
patent: 0 344 519 (1993-04-01), None
patent: 0 509 359 (1996-02-01), None
patent: 0 703 216 (1996-03-01), None
patent: 0 870 762 (1998-10-01), None
patent: 0 947 502 (1999-10-01), None
patent: 03227922 (1991-10-01), None
patent: 06072947 (1994-03-01), None
patent: 3-227922 (1998-12-01), None
patent: 00355551 (2000-12-01), None
patent: 2003238407 (2003-08-01), None
patent: WO-91/13908 (1991-09-01), None
patent: WO 94/00420 (1994-01-01), None
patent: WO-95/07249 (1995-03-01), None
patent: WO 95/18610 (1995-07-01), None
patent: WO 96/11192 (1996-04-01), None
patent: WO 96/27585 (1996-09-01), None
patent: WO 96/41625 (1996-12-01), None
patent: WO 97/29774 (1997-08-01), None
patent: WO 97/29775 (1997-08-01), None
patent: WO-97/34885 (1997-09-01), None
patent: WO 98/09943 (1998-03-01), None
patent: WO 98/13347 (1998-04-01), None
patent: WO 98/40354 (1998-09-01), None
patent: WO 98/40364 (1998-09-01), None
patent: WO 98/40370 (1998-09-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/43954 (1998-10-01), None
patent: WO-99/52942 (1999-10-01), None
patent: WO-99/59964 (1999-11-01), None
patent: WO 00/43001 (2000-07-01), None
patent: WO 00/50577 (2000-08-01), None
patent: WO 00/59864 (2000-10-01), None
patent: WO-01/17528 (2001-03-01), None
patent: WO 01/34199 (2001-05-01), None
patent: WO 01/57025 (2001-08-01), None
patent: WO 01/96347 (2001-12-01), None
patent: WO 02/05825 (2002-01-01), None
patent: WO 02/060378 (2002-08-01), None
patent: WO 03/035670 (2003-05-01), None
patent: WO 03/037349 (2003-05-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/086282 (2003-10-01), None
patent: WO 03/103602 (2003-12-01), None
patent: WO 2004/002409 (2004-01-01), None
patent: WO 2004/012686 (2004-02-01), None
patent: WO 2004/024186 (2004-03-01), None
patent: WO-2004/028341 (2004-04-01), None
patent: WO 2004/035741 (2004-04-01), None
patent: WO-2004/035746 (2004-04-01), None
patent: WO 2004/047648 (2004-06-01), None
patent: WO 2004/052839 (2004-06-01), None
patent: WO 2004/055520 (2004-07-01), None
patent: WO-2005/027886 (2005-03-01), None
Buxton, The New England J. of Med. vol. 352(5):2638-2640, 2005.
Jay N. Cohn, M.D., University of Minnesota Medical School, Minneapolis, Minnesota) vol. 57(8) 1998.
Gompertz et al. Chest vol. 122, 289-294, 2002.
Folco et al.Am. J. Respir. Crit. Care Med. vol. 161 pp. S112-S116 2000.
Byrum et al. J. Exp. Med vol. 185(6) 1065-1075 1997.
Rossoni et al. The J. Pharmcology and Exp. Therapeutics, vol. 276(1), 335-341, 1996.
Am. J. Med. 1992, 93 Abstract only.
Chemplavi Kottayam Medical college, Magazine, 1970 1-6.
Batkai et al., “Inhibition of 4-lipoxygenase Improves Regional Myocardial Function After Repetitive Ischemia in the Rat Heart,” Pluegers Archiv., Springer Verlag, 430(4):R18 (1995).
Dib et al., “A Comprehensive Genetic Map of the Human Genome Based on 5,264 Microsatellites,” Nature, 380:152-154 (1996).
European Search Report for EP 03 78 3063 dated Jul. 18, 2006.
Genbank Accession No. Z52271.
Genbank Accession No. Z24370.
Hatzelmann et al., Inversely-correlated Inhibition of Human 5-lipoxygenase Activity by BAY X1005 and Other Quinoline Derivatives in Intact Cells and a Cell-Free System: Implications for the Function of 5-lipoxygenase Activating Protein, Biochemical Pharmacology, 47:2259-2268 (1994).
Koshino et al., “Novel Polymorphism of the 5-lipoxygenase Activating Protein (FLAP) Promoter Gene Associated with Asthma,” Molecular Cell Biology Research Communiciations, 2:32-35 (1999).
Yandava et al., “Cytogenetic and Radiation Hybrid Mapping of Human Arachidonate 5-lipoxygenase-activating Protein (ALOX5AP) to Chromosome 13q12,” Genmoics, 56:131-133 (1999).
Ahmed et al., Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary γ-Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions,Circ., 104:856-859 (2001).
Aiello et al., Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells In Mice,Arterioscler. Thromb. Vasc. Biol., 22:443-449 (2002).
Allen et al., Enhanced Excretion of Urinary Leukotriene E4in Coronary Artery Disease and After Coronary Artery Bypass Surgery, Coronary Artery Disease, 4: 899-904 (1993).
Allen et al., Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries,Circulation, 97:2406-2413 (1998).
Andresdottir et al., Fifteen Percent of Myocardial Infarctions and Coronary Revascularizations Explained by Family History Unrelated to Conventional Risk Factors,European Heart Journal, 23:1655-1663 (2002).
Askonas et al., Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(Phenylmethyl)Phenoxy]Propyl]Amino]Propanoic Acid HCI), a Potent and Selective Inhibitor of Leukotriene A4Hydrolase I: In Vitro Studies,JPET, 300:577-582 (2002).
Bakr et al., 5-Lipoxygenase and Leukotriene A4Hydrolase Expression in Primary Nephrotic Syndrome,Pediatr Nephrol, 19:396-399 (2004).
Barone et al., Time-Related Changes in Myeloperoxidase Activity and Leukotriene B4Receptor Binding Reflect Leukocyte Influx in Cerebral Focal Stroke,Mol. Chem. Neuropathol., 24:13-30 (1995).
Barth, J., Which Tools are in your Cardiac Workshop? Carotid Ultrasound, Endothelial Function, and Magnetic Resonance Imaging,Am. J. Cardiol., 87(suppl) 8A-14A (2001).
Bermudez et al, Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women,Arterioscler Thromb Vasc Biol., 22:1668-1673 (2002).
Birke at al., In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4Receptor Antagonist,JPET, 297:458-466 (2001).
Blackie et al., The Identification of Clinical Candidate SB-480848: A Potent Inhibitor of Lipoprotein-Associated Phospholipase A2,Bioorganic Med. Chem. Lett., 13:1067-1070 (2003).
Blake et al, C-Reactive Protein, Subclinical Atherosclerosis, and Risk of Cardiovascular Events,Arterioscler. Thromb. Vasc Biol., 22:1512-1513 (2002).
Blake et al., Projected Life-Expectancy Gains With Statin Therapy for Individuals With Elevated C-Reactive Protein Levels,JACC, 40:49-55 (2002).
Boyd et al., N-1 Substituted Pyrimidin-4-Ones: Novel, Orally Active Inhibitors of Lipoprotein-Associated Phospholipase A2,Bioorganic Med. Chem. Lett., 10:2557-2561 (2000).
Brennan et al., Prognostic Value of Myeloperoxidase in Patients with Chest Pain,N. En
Gulcher Jeffrey R.
Gurney Mark
Hákonarson Hákon
Helgadottir Anna
deCODE Genetics ehf.
Gembeh Shirley V
Hartley Michael G
Marshall & Gerstein & Borun LLP
LandOfFree
Susceptibility gene for myocardial infarction, stroke, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Susceptibility gene for myocardial infarction, stroke, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Susceptibility gene for myocardial infarction, stroke, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190639